Yale-Led Team Develops Nanosensors for Detecting Biomarkers in Whole Blood | GenomeWeb

This story originally ran on Jan. 6.

By Tony Fong

A team of researchers led by Yale scientists has created a nanosensor device that they said can detect cancer protein biomarkers in whole blood for the first time, representing a "paradigm shift in label-free electronic sensing of biomolecules."

The researchers have launched a company, Altura Diagnostics, to explore opportunities to commercialize the technology, but the firm is still in the very early stages of development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.